2022
Long-Term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children with Neurogenic Detrusor Overactivity
Franco I, Dobremez E, Hoebeke P, Titanji W, Yushmanova I, Jenkins B, Austin P. Long-Term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children with Neurogenic Detrusor Overactivity. Toxicon 2022, 214: s18-s19. DOI: 10.1016/j.toxicon.2021.11.049.Peer-Reviewed Original Research
2021
P1063 Long-term safety and tolerability of repeated treatments with onabotulinumtoxinA in children with neurogenic detrusor overactivity
Franco I, Dobremez E, Hoebeke P, Titanji W, Yushmanova I, Jenkins B, Austin P. P1063 Long-term safety and tolerability of repeated treatments with onabotulinumtoxinA in children with neurogenic detrusor overactivity. European Urology 2021, 79: s1506-s1507. DOI: 10.1016/s0302-2838(21)01435-4.Peer-Reviewed Original ResearchEfficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial
Austin P, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, Jenkins B, Hoebeke P. Efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial. Toxicon 2021, 190: s6. DOI: 10.1016/j.toxicon.2020.11.352.Peer-Reviewed Original Research
2020
751 Efficacy and safety of three active doses of onabotulinum toxin A for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial
Hoebeke P, Austin P, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, Jenkins B. 751 Efficacy and safety of three active doses of onabotulinum toxin A for the treatment of neurogenic detrusor overactivity in children: Results of a randomized controlled clinical trial. European Urology Open Science 2020, 19: e1147. DOI: 10.1016/s2666-1683(20)33351-6.Peer-Reviewed Original Research